Published in Hepatitis Weekly, September 16th, 2002
"We studied 20 consecutive hepatitis B surface antigen (HBsAg)-positive recipients of allogeneic hematopoietic cell transplantation who received lamivudine 100 mg daily starting a week before transplantation until week 52 after transplantation," said George K.K. Lau, the report's lead investigator.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly